CBC Group, in partnership with the Mubadala Investment Company, has completed the strategic acquisition of Union Chimique Belge's (UCB) mature neurology and allergy business in China for $680m.
Strategic acquisition under CBC's buyout strategy expected to drive significant value creation and positive patient outcomes through CBC's proven investor-operator approach and solution.
The well-established and trusted medicine portfolio will serve as an anchor asset as CBC builds out a leading integrated central nervous system (CNS) biopharma platform in China, where the market ...
LA PAZ, Nov 26 (Reuters) - Bolivia's government and Chinese consortium CBC, which includes battery manufacturer CATL (300750.SZ), opens new tab, have signed an agreement for CBC to build two ...
30, 2024 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare ... company UCB's mature neurology and allergy business in China, in partnership with Mubadala Investment Company, the Abu ...